Mikhail Anan-Caga

London, ENG W120NN, United Kingdom

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 9 publications

Anti-Malondialdehyde Low-Density Lipoprotein Antibodies and Valvular Calcification: A Substudy of the SCOT-HEART Trial.

Anti-Malondialdehyde Low-Density Lipoprotein Antibodies and Valvular Calcification: A Substudy of the SCOT-HEART Trial.

Journal: Journal of the American Heart Association
Published: November 03, 2025

Antimalondialdehyde Low-Density Lipoprotein Antibody Levels Predict Low-Attenuation Plaque in the SCOT-HEART Trial.

Antimalondialdehyde Low-Density Lipoprotein Antibody Levels Predict Low-Attenuation Plaque in the SCOT-HEART Trial.

Journal: JACC. Cardiovascular imaging
Published: April 06, 2022

Depletion of Homeostatic Antibodies against Malondialdehyde-Modified Low-Density Lipoprotein Correlates with Adverse Events in Major Vascular Surgery.

Depletion of Homeostatic Antibodies against Malondialdehyde-Modified Low-Density Lipoprotein Correlates with Adverse Events in Major Vascular Surgery.

Journal: Antioxidants (Basel, Switzerland)
Published: November 17, 2021

The Placebo-Controlled Effect of Percutaneous Coronary Intervention on Exercise Induced Changes in Anti-Malondialdehyde-LDL Antibody Levels in Stable Coronary Artery Disease: A Substudy of the ORBITA Trial.

The Placebo-Controlled Effect of Percutaneous Coronary Intervention on Exercise Induced Changes in Anti-Malondialdehyde-LDL Antibody Levels in Stable Coronary Artery Disease: A Substudy of the ORBITA Trial.

Journal: Frontiers in cardiovascular medicine
Published: August 11, 2021

Monoclonal Autoantibody Against a Cryptic Epitope on Tissue-Adherent Low-Density Lipoprotein for Molecular Imaging in Atherosclerosis.

Monoclonal Autoantibody Against a Cryptic Epitope on Tissue-Adherent Low-Density Lipoprotein for Molecular Imaging in Atherosclerosis.

Journal: JACC. Cardiovascular imaging
Published: August 05, 2021

A Novel Immunoassay for Malondialdehyde-Conjugated Low-Density Lipoprotein Measures Dynamic Changes in the Blood of Patients Undergoing Coronary Artery Bypass Graft Surgery.

A Novel Immunoassay for Malondialdehyde-Conjugated Low-Density Lipoprotein Measures Dynamic Changes in the Blood of Patients Undergoing Coronary Artery Bypass Graft Surgery.

Journal: Antioxidants (Basel, Switzerland)
Published: June 29, 2021

Oxidised LDL and Anti-Oxidised LDL Antibodies Are Reduced by Lipoprotein Apheresis in a Randomised Controlled Trial on Patients with Refractory Angina and Elevated Lipoprotein(a).

Oxidised LDL and Anti-Oxidised LDL Antibodies Are Reduced by Lipoprotein Apheresis in a Randomised Controlled Trial on Patients with Refractory Angina and Elevated Lipoprotein(a).

Journal: Antioxidants (Basel, Switzerland)
Published: November 21, 2020

IgM anti-malondialdehyde low density lipoprotein antibody levels indicate coronary heart disease and necrotic core characteristics in the Nordic Diltiazem (NORDIL) study and the Integrated Imaging and Biomarker Study 3 (IBIS-3).

IgM anti-malondialdehyde low density lipoprotein antibody levels indicate coronary heart disease and necrotic core characteristics in the Nordic Diltiazem (NORDIL) study and the Integrated Imaging and Biomarker Study 3 (IBIS-3).

Journal: EBioMedicine
Published: May 27, 2018

High Serum Immunoglobulin G and M Levels Predict Freedom From Adverse Cardiovascular Events in Hypertension: A Nested Case-Control Substudy of the Anglo-Scandinavian Cardiac Outcomes Trial.

High Serum Immunoglobulin G and M Levels Predict Freedom From Adverse Cardiovascular Events in Hypertension: A Nested Case-Control Substudy of the Anglo-Scandinavian Cardiac Outcomes Trial.

Journal: EBioMedicine
Published: April 25, 2016
Showing 1-9 of 9

Last Updated: 09/26/2026